View in EDS

Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.

Saved in:
Bibliographic Details
Title: Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events.
Authors: Schwarz, Carsten1 (AUTHOR) carsten.schwarz@charite.de, Sutharsan, Sivagurunathan2 (AUTHOR), Epaud, Ralph3 (AUTHOR), Klingsberg, Ross C.4 (AUTHOR), Fischer, Rainald5 (AUTHOR), Rowe, Steven M.6 (AUTHOR), Audhya, Paul K.7 (AUTHOR), Ahluwalia, Neil8 (AUTHOR), You, Xiaojun7 (AUTHOR), Ferro, Thomas J.7 (AUTHOR), Duncan, Margaret E.8 (AUTHOR), Bruinsma, Bote G.8 (AUTHOR)
Source: Journal of Cystic Fibrosis. Mar2021, Vol. 20 Issue 2, p228-233. 6p.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first